Ljubinka Veličković-Janković

Ljubinka Veličković-Janković

Auto-generated profile, based on publicly available information

Ljubinka Veličković-Janković

Clinical Center, 18000 Niš, Serbia

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 September 2020 in Diagnostics
Verified
Journal Article
Open access
PDF file
Andrej VeljkovicAndrej Veljkovic
Andrej Veljkovic
JHJovan Hadži-Dokić
Jovan Hadži-Dokić
DSDušan Sokolović
Dušan Sokolović
DBDragoslav Bašić
Dragoslav Bašić
LVLjubinka Veličković-Janković
Ljubinka Veličković-Janković
Gordana KocicGordana Kocic
Gordana Kocic
Prostate cancer (PC) is one of the most frequent malignancies. Better biomarkers are constantly wanted, such as those which can help with the prediction of cancer behavior. What is also needed is a marker which may serve as a possible therapeutic target. Oxidative stress (OS), which is a hallmark of cancer, is included in the pathogenesis and progression of PC. We have conducted the present study to determine whether xanthine oxidase/dehydrogenase activity is the source of OS in prostate tissue. We have also determined the concentration of TBA-reactive substances (TBARS) and advanced oxidation protein products (AOPP), as well as the activity of catalase. Xanthine oxidase (XO) activity is significantly higher (p < 0.001) in tumor tissue when compared to the control healthy tissue. The concentration of TBARS (p < 0.001) and AOPP (p < 0.05) are also higher in tumor tissue. Catalase has raised its activity (p < 0.05) versus the control. There is also a strong correlation between XO activity and prostate-specific antigen (PSA) levels in the serum. These results indicate a significant role of XO activity in OS in prostate carcinogenesis, and it could be a possible theranostic biomarker, which can be important for a better understanding of the disease, its evolution, and prognosis. A promising treatment may be using XO inhibitors such as allopurinol as adjuvant therapy.